Skip to main content
Equibles
ASND logo

ASND · Ascendis Pharma A/S

Track ASND — free

Use ASND with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about ASND

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$248.50 +2.27 (+0.92%) At close · Aug 14
Market Cap
$16.19B
Shares
65.59M

Ascendis Pharma A/S Earnings Call Transcripts

Every quarterly earnings call for Ascendis Pharma A/S (ASND) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Earnings call
FY26 · Q2
2026-08-13
Q2 2026 Ascendis Pharma Earnings Conference Call
Confident tone Global commercialization infrastructure TransCon Combination Trial (COACH) results UVA Well (TransCon hGH) launch and competition
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-04-08
Ascendis Pharma A/S Q1 FY2026 Earnings Call
Confident tone YORVIPATH commercial performance YUVIWEL launch (TransCon CNP) Competition in hypoparathyroidism
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-01-08
Ascendis Pharma A/S Q4 FY2025 Earnings Call
Confident tone Yorvipath commercial launch and growth TransCon CNP and combination therapy in achondroplasia Skytrofa / TransCon Growth Hormone
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-09-30
Ascendis Pharma A/S Q3 FY2025 Earnings Call
Confident tone Eurvipath commercial launch Growth disorders portfolio Financial performance and profitability
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-07-12
Ascendis Pharma A/S Q2 FY2025 Earnings Call
Confident tone YORVIPATH commercial launch TransCon CNP in achondroplasia Combination therapy / COACH trial
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-03-31
Ascendis Pharma A/S Q1 FY2025 Earnings Call
Confident tone YORVIPATH U.S. launch performance Path to cash flow positive and financial outlook SKYTROFA franchise and label expansion
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2024-12-31
Ascendis Pharma A/S Q4 FY2024 Earnings Call
Confident tone YORVIPATH U.S. launch and hypoparathyroidism opportunity TransCon CNP and achondroplasia SKYTROFA growth hormone franchise
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-09-30
Ascendis Pharma A/S Q3 FY2024 Earnings Call
Confident tone SKYTROFA growth and U.S. commercial performance YORVIPATH U.S. launch readiness Full-year 2024 revenue guidance
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-06-30
Ascendis Pharma A/S Q2 FY2024 Earnings Call
Confident tone SKYTROFA Market Access Reset YORVIPATH US Launch YORVIPATH Europe Commercialization
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-03-31
Ascendis Pharma A/S Q1 FY2024 Earnings Call
Confident tone SKYTROFA U.S. commercial performance TransCon CNP achondroplasia program TransCon PTH U.S. PDUFA and prelaunch
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2023-12-31
Ascendis Pharma A/S Q4 FY2023 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-09-30
Ascendis Pharma A/S Q3 FY2023 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-06-30
Ascendis Pharma A/S Q2 FY2023 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-03-31
Ascendis Pharma A/S Q1 FY2023 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2022-12-31
Ascendis Pharma A/S Q4 FY2022 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-09-30
Ascendis Pharma A/S Q3 FY2022 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-06-30
Ascendis Pharma A/S Q2 FY2022 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-03-31
Ascendis Pharma A/S Q1 FY2022 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2021-12-31
Ascendis Pharma A/S Q4 FY2021 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-09-30
Ascendis Pharma A/S Q3 FY2021 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-06-30
Ascendis Pharma A/S Q2 FY2021 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-03-31
Ascendis Pharma A/S Q1 FY2021 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2020-12-31
Ascendis Pharma A/S Q4 FY2020 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-09-30
Ascendis Pharma A/S Q3 FY2020 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-06-30
Ascendis Pharma A/S Q2 FY2020 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-03-31
Ascendis Pharma A/S Q1 FY2020 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Showing 1–26 of 26 earnings calls
Key facts CIK 1612042 CUSIP K08588103 13F (30d) 299 filings 295 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)